Table 3

Clinical response (SRI) to treatment at weeks 12 and 24: overall ITT analysis

Lupuzor
Group 1 (200 μg every 4 weeks)Group 2 (200 μg every 2 weeks)Group 3 (placebo)
Week 12n=49n=51n=47
Responders, n (%)26 (53.1)23 (45.1)17 (36.2)
p=0.048p=0.18
Week 24n=49n=51n=49
Responders, n (%)29 (59.2)30 (58.8)26 (53.1)
p=0.27p=0.28
  • p Values compare Lupuzor with placebo. Drop-outs are considered as non-responders.

  • ITT, intention-to-treat; SRI, SLE Responder Index.